Long Road Investment Counsel LLC maintained its stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,200 shares of the biopharmaceutical company’s stock at the end of the second quarter. Gilead Sciences accounts for approximately 1.5% of Long Road Investment Counsel LLC’s portfolio, making the stock its 28th biggest position. Long Road Investment Counsel LLC’s holdings in Gilead Sciences were worth $1,996,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Marshall & Sullivan Inc. WA increased its holdings in shares of Gilead Sciences by 0.6% in the 2nd quarter. Marshall & Sullivan Inc. WA now owns 21,462 shares of the biopharmaceutical company’s stock valued at $1,519,000 after purchasing an additional 125 shares in the last quarter. Key Square Capital Management LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $43,990,000. Martin Investment Management LLC grew its stake in Gilead Sciences by 2.4% in the 2nd quarter. Martin Investment Management LLC now owns 144,265 shares of the biopharmaceutical company’s stock valued at $10,211,000 after acquiring an additional 3,380 shares during the last quarter. Bank Pictet & Cie Asia Ltd. acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $285,000. Finally, Banque Pictet & Cie SA grew its stake in Gilead Sciences by 11.9% in the 2nd quarter. Banque Pictet & Cie SA now owns 204,356 shares of the biopharmaceutical company’s stock valued at $14,464,000 after acquiring an additional 21,737 shares during the last quarter. Institutional investors and hedge funds own 74.38% of the company’s stock.
WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://sportsperspectives.com/2017/11/10/gilead-sciences-inc-gild-stake-maintained-by-long-road-investment-counsel-llc.html.
Gilead Sciences, Inc. (GILD) opened at $73.02 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 4.74 and a current ratio of 3.68. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The firm has a market capitalization of $95,488.27, a PE ratio of 7.63, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the previous year, the business posted $2.75 EPS. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. equities research analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.85%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.
GILD has been the topic of a number of research reports. BMO Capital Markets reissued a “hold” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research note on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price objective on the stock in a research note on Wednesday, September 6th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $85.92.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP James R. Meyers sold 60,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $83.19, for a total value of $4,991,400.00. Following the transaction, the executive vice president now directly owns 62,715 shares in the company, valued at approximately $5,217,260.85. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 446,819 shares of company stock worth $36,269,486. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.